Compare ATOM & SMTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATOM | SMTI |
|---|---|---|
| Founded | 2001 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.2M | 182.6M |
| IPO Year | 2016 | 2008 |
| Metric | ATOM | SMTI |
|---|---|---|
| Price | $4.19 | $17.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | ★ 833.2K | 73.0K |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.41 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $62,000.00 | ★ $15,586,976.00 |
| Revenue This Year | $527.69 | $17.31 |
| Revenue Next Year | N/A | $12.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.47 |
| 52 Week Low | $1.89 | $16.05 |
| 52 Week High | $7.45 | $35.70 |
| Indicator | ATOM | SMTI |
|---|---|---|
| Relative Strength Index (RSI) | 48.21 | 39.40 |
| Support Level | $3.14 | $16.05 |
| Resistance Level | $5.27 | $21.14 |
| Average True Range (ATR) | 0.39 | 1.22 |
| MACD | -0.08 | -0.04 |
| Stochastic Oscillator | 42.74 | 26.87 |
Atomera Inc is engaged in the business of developing, commercializing, and licensing proprietary processes and technologies for the semiconductor industry. The company's technology, named Mears Silicon Technology, or MST, is a thin film of re-engineered silicon, typically 100 to 300 angstroms (or approximately 20 to 60 silicon atomic unit cells) thick. MST can be applied as a transistor channel enhancement to CMOS-type transistors, the majority of widely used in the semiconductor industry. The company's silicon technology can be used for applications like Analog, DRAM, logic, processors, and SRAM. Geographically, it generates maximum revenue from North America.
Sanara MedTech Inc is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the chronic and surgical wound and skincare markets. Its portfolio of products and services allows it to deliver comprehensive wound and skincare solutions for patients in all care settings, including acute and post-acute. Its surgical wound care products are CellerateRX Surgical Activated Collagen. Its chronic wound care products are BIAKOS Skin and Wound Cleanser, and BIAKOS Skin and Wound Gel.